{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:16:02Z","timestamp":1794118562951,"version":"4.8.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.annonc.2021.06.023","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:15:08Z","timestamp":1625570108000},"page":"1216-1235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":770,"title":["Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021"],"prefix":"10.1016","volume":"32","author":[{"given":"H.J.","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisse","family":"Bretel Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Fitzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebatallah","family":"Gamal El Din Mohamed Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahadir","family":"Gulluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Ilbawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sedlmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Semiglazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joerg","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Spanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Tesarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Tjulandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez","family":"Vaz Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.06.023_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2021.06.023_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1475-6773.13596","article-title":"Disruptions in preventive care: mammograms during the COVID-19 pandemic","volume":"56","author":"Song","year":"2021","journal-title":"Health Serv Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rcl.2020.09.008","article-title":"The Impact of the COVID-19 pandemic on breast imaging","volume":"59","author":"Freer","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.annonc.2021.06.023_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A\u00a0study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A\u00a0population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib8","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors \u2013 an analysis of 2765 patients from neoadjuvant clinical trials","volume":"148","author":"Villegas","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib11","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","article-title":"Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98","volume":"25","author":"Viale","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2021.06.023_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-018-05112-9","article-title":"Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII\u00a0+ IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial","volume":"176","author":"Denkert","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2021.06.023_bib14","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working Group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2021.06.023_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.annonc.2021.06.023_bib17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-043015-075227","article-title":"Why are there so many mastectomies in the United States?","volume":"68","author":"Mamtani","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamasurg.2016.4749","article-title":"Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer","volume":"152","author":"Jagsi","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-017-4324-3","article-title":"Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer","volume":"165","author":"Houssami","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2021.06.023_bib21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.06.023_bib22","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of fast: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib23","volume":"81","author":"Kunkler","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib24","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2019.11.024","article-title":"Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial","volume":"127","author":"Fastner","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib26","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMp1205737","article-title":"Pathological complete response and accelerated drug approval in early breast cancer","volume":"366","author":"Prowell","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer","volume":"110","author":"Semiglazov","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-020-01288-5","article-title":"Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib30","volume":"81","author":"Harbeck","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib31","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib33","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.06.023_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer","volume":"310","author":"Boughey","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.annonc.2021.06.023_bib36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib38","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib39","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","article-title":"Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy","volume":"28","author":"Almahariq","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.annonc.2021.06.023_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.annonc.2021.06.023_bib43","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib44","volume":"78","author":"Gnant","year":"2018","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib46","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib47","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib49","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014The Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib50","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib52","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib53","volume":"81","author":"Kalinsky","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib54","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","article-title":"Longer therapy, Iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib55","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials","volume":"34","author":"Regan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib56","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma In Situ in a randomized Phase III Trial: The DBCG HYPO Trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib57","article-title":"Abstract GS2-04: a randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07\/TROG 07.01), in General Session Abstracts","volume":"81","author":"Chua","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib58","article-title":"Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ, in General Session Abstracts","volume":"81","author":"Sestak","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib61","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1245\/s10434-012-2404-5","article-title":"Repeating conservative surgery after Ipsilateral breast tumor reappearance: criteria for selecting the best candidates","volume":"19","author":"Gentilini","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib62","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","article-title":"Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR Trial","volume":"36","author":"Wapnir","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1470-2045(13)70589-8","article-title":"Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial","volume":"15","author":"Aebi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib64","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","article-title":"Impact of breast surgery in primary metastasized breast cancer","volume":"269","author":"Fitzal","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib65","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","article-title":"Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01","volume":"25","author":"Soran","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2","article-title":"A\u00a0randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)","volume":"38","author":"Khan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib67","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/SLA.0000000000002621","article-title":"Surgical resection of the primary tumor in women with de novo stage IV breast cancer","volume":"269","author":"Lane","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib68","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2016.21038","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.annonc.2021.06.023_bib69","article-title":"Abstract GS2-10: targeting depressive symptoms in younger breast cancer survivors: a randomized controlled trial of mindfulness meditation and survivorship education, in General Session Abstracts","volume":"81","author":"Ganz","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib70","doi-asserted-by":"crossref","first-page":"e1846","DOI":"10.1634\/theoncologist.2020-0417","volume":"25","author":"S\u00e1nchez-Rovira","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2021.06.023_bib71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib72","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib73","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.annonc.2021.06.023_bib74","doi-asserted-by":"crossref","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","article-title":"Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)","volume":"4","author":"Leon-Ferre","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.annonc.2021.06.023_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-020-05622-5","article-title":"Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy","volume":"181","author":"Ribi","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2021.06.023_bib76","doi-asserted-by":"crossref","first-page":"e000793","DOI":"10.1136\/esmoopen-2020-000793","article-title":"ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer","volume":"5","author":"de Azambuja","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2021.06.023_bib77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clon.2020.03.006","article-title":"International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic","volume":"32","author":"Coles","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib78","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","article-title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium","volume":"181","author":"Dietz","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2021.06.023_bib79","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/cncr.33460","article-title":"Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures","volume":"127","author":"Nyante","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib81","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I\u2013III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib82","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clon.2020.12.008","article-title":"The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an international consortium report","volume":"33","author":"Marta","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2019.04.010","article-title":"ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer","volume":"137","author":"Kaidar-Person","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2020.12.010","article-title":"Why is appropriate healthcare inaccessible for many European breast cancer patients? \u2013 the EBCC 12 manifesto","volume":"55","author":"Cardoso","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.annonc.2021.06.023_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1200\/JCO.18.00982","article-title":"Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK\/06\/003) phase III randomized controlled trial","volume":"37","author":"Bhattacharya","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib86","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial","volume":"38","author":"Meattini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib87","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","article-title":"External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial","volume":"394","author":"Whelan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.06.023_bib88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.rpor.2020.07.008","article-title":"Apples and oranges: comparing partial breast irradiation techniques","volume":"25","author":"Kaidar-Person","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.annonc.2021.06.023_bib89","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","article-title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","volume":"394","author":"Vicini","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.annonc.2021.06.023_bib90","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1245\/s10434-021-09621-8","article-title":"The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (protocol BOMET MF 14-01): a multi-center, prospective registry study","volume":"28","author":"Soran","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib91","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib92","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib93","article-title":"Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy","author":"Martelli","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib94","article-title":"A\u00a0prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients","author":"Kuemmel","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.06.023_bib95","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1470-2045(20)30084-X","article-title":"Knowledge gaps in oncoplastic breast surgery","volume":"21","author":"Weber","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib96","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(20)30580-5","article-title":"Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox","volume":"22","author":"Dubsky","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib97","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2020.04.020","article-title":"The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial","volume":"134","author":"Dubsky","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib99","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1158\/1078-0432.CCR-20-4102","article-title":"Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy","volume":"27","author":"Pascual","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib100","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2021.06.023_bib101","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","article-title":"A\u00a0multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib102","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-20-0260","article-title":"Prognostic value of EndoPredict in women with hormone receptor-positive, HER2-negative invasive lobular breast cancer","volume":"26","author":"Sestak","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib103","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen\u2014to offer more? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib104","article-title":"Abstract GS4-09: correlative studies of the breast cancer index (HOXB13\/IL17BR) and ER, PR, AR, AR\/ER ratio and Ki67 for prediction of extended endocrine benefit: a trans-aTTom study, in General Session Abstracts","volume":"81","author":"Sgroi","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib106","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.06.023_bib107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.clbc.2020.09.011","article-title":"nextMONARCH: abemaciclib monotherapy or combined with tamoxifen for metastatic breast cancer","volume":"21","author":"Hamilton","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib108","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib109","article-title":"Abstract GS4-02: E2112: randomized phase 3 trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group, in General Session Abstracts","volume":"80","author":"Connolly","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib110","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib111","article-title":"Abstract GS1-05: TBCRC 033: a randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT), in General Session Abstracts","volume":"80","author":"Tolaney","year":"2020","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET Trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annonc.2021.06.023_bib113","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib114","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib116","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment","volume":"325","author":"Wang","year":"2021","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.annonc.2021.06.023_bib118","article-title":"Abstract GS1-08: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): an open-label, randomised, multicentre, phase 3 trial, in General Session Abstracts","volume":"80","author":"Li","year":"2020","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib119","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.06.023_bib120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.06.023_bib121","article-title":"Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 michelangelo randomized study, in General Session Abstracts","volume":"80","author":"Gianni","year":"2020","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2021.06.023_bib122","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib123","doi-asserted-by":"crossref","first-page":"S1147","DOI":"10.1016\/j.annonc.2020.08.2243","article-title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) \u00b1 atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"Miles","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.06.023_bib124","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.06.023_bib125","doi-asserted-by":"crossref","first-page":"S1149","DOI":"10.1016\/j.annonc.2020.08.2245","article-title":"LBA17 ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"Bardia","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421021049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421021049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:03:49Z","timestamp":1760335429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421021049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0923753421021049"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}